NMI-ChoroidAI
by NetraMind Innovations, Inc.
· Based in United States →
— Comprehensive AI-Powered Ophthalmic Data Analysis, Screening & Prediction
Overview
NMI-ChoroidAI by NetraMind Innovations, Inc. is an artificial intelligence tool designed for the analysis of optical coherence tomography (OCT) images of the eye.
- What it does: The tool quantifies choroidal thickness and vascularity. It processes OCT scans to provide objective measurements of the choroid, a vascular layer of the eye.
- Who it is for: NMI-ChoroidAI is intended for ophthalmologists and retina specialists. It may be utilized in various care settings, including ophthalmic clinics and academic medical centers, where OCT imaging is routinely performed.
- How it fits a clinical or practice workflow: The tool integrates into the image analysis workflow following OCT acquisition. It provides automated measurements that can assist clinicians in evaluating choroidal structure, potentially aiding in the assessment and management of various retinal conditions.
- Notable capabilities: NMI-ChoroidAI offers automated, quantitative analysis of choroidal parameters from OCT images, aiming to provide consistent and objective data.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered automated choroid boundary segmentation (inner/outer)
- Analysis of choroidal vasculature
- Precise 3D segmentation of the choroid
- Comprehensive measurements of choroidal thickness, volume, and Choroidal Vascularity Index (CVI)
- Results delivered in ETDRS grid format and detailed tabulated reports
- Seamless integration into clinical workflows and research protocols
- AI-accelerated segmentation with clinician oversight
- Intuitive visualization tools
- CVI heat mapping
- Compatibility with HEYEX 2
Use Cases
- Understanding and managing retinal diseases such as AMD, CSCR, and pathological myopia
- Objective, reproducible, and automated choroidal analysis for clinicians
- Accelerating research into ocular diseases
- Enhancing diagnostic confidence in choroidal health
- Streamlining workflow for choroidal analysis
- Supporting clinical trials and translational research with standardized, high-quality analysis of ophthalmic imaging data
What Physicians Need to Know
Retinal Image Analysis (Fundus/OCT)
NMI-ChoroidAI primarily focuses on analyzing SPECTRALISu00ae OCT volume data. It automatically segments the inner and outer choroidal boundaries and analyzes choroidal vasculature, providing precise 3D segmentation and comprehensive measurements of choroidal thickness, volume, and the Choroidal Vascularity Index (CVI). [1, 2, 5] The results are delivered in ETDRS grid format and detailed tabulated reports. [1, 2, 5] The tool also offers advanced choroid analysis, including 3D vasculature visualization and thickness heatmaps. [6] While its core strength is OCT analysis, NetraMind Innovations also offers general retinal image analysis and detection of retinal disease biomarkers. [7]
Glaucoma Detection
NMI-ChoroidAI's primary focus is on choroidal analysis for retinal diseases. [1, 2, 5] While AI is increasingly applied to glaucoma management, including OCT analysis for retinal nerve fiber layer thickness and optic disc structure, [19, 25] there is no specific information indicating NMI-ChoroidAI's direct application or accuracy in glaucoma detection.
Age-Related Macular Degeneration Screening
Accurate assessment of the choroid, which NMI-ChoroidAI provides, is essential in understanding and managing retinal diseases such as Age-Related Macular Degeneration (AMD). [1, 2, 5] Choroidal abnormalities and alterations are critical in AMD progression, and choroidal imaging biomarkers, including choroidal thickness, volume, and vascularity index, are valuable in evaluating AMD patients. [30, 31, 32] NetraMind Innovations also lists 'Wet AMD Prediction' as one of its products. [7] Studies have shown that AI models can detect and classify choroidal neovascularization (CNV), a complication of AMD, with high accuracy (e.g., 95% sensitivity at 95% specificity). [12, 13]
Autonomous vs Assistive Diagnosis
NMI-ChoroidAI is explicitly stated as an assistive tool. [1, 5] It is not intended to replace professional medical judgment or be used for diagnosis, treatment, or prevention of any disease. [1, 5] The solution provides AI-accelerated segmentation with clinician oversight, intuitive visualization tools, and streamlined workflow compatibility. [1] A 'human-in-the-loop' approach is considered critical for AI in ophthalmology, where manual verification serves as a mandatory quality control step. [4]
Point-of-Care Deployment
While NMI-ChoroidAI is available via the Heidelberg AppWay marketplace, [1, 2, 5] which aims to empower eye care professionals and researchers, [1, 5] there is no specific mention of NMI-ChoroidAI being designed for point-of-care deployment. Point-of-care diagnostics generally involve rapid diagnostic results in non-laboratory settings, often utilizing portable devices. [28, 37, 39]
Screening Program Integration
NMI-ChoroidAI's results are delivered in ETDRS grid format and detailed tabulated reports, designed for seamless integration into research protocols. [1, 2, 5] Its availability on the Heidelberg AppWay marketplace and export options (ETDRS grids, CSV/JSON) are designed to fit existing research pipelines. [3] NetraMind Innovations also offers comprehensive ophthalmic data management and analysis, enabling users to filter and analyze data based on clinical, demographic, and imaging filters. [7]
Sensitivity & Specificity Data
For choroidal boundary detection in eyes with geographic atrophy using NMI-ChoroidAI, a study reported a strict accuracy (Grade 0) of 94.8% for the choroidal inner boundary (CIB), with a weighted F1 score of 0.97 and precision of 1.00. [4] For the choroidal outer boundary (COB), strict accuracy was 81.0% (weighted F1 score: 0.89), but when minor deviations (u226433%) were considered acceptable, COB acceptability increased to 94.2%. [4] Another study on AI models for choroid visualization in myopia found sensitivities ranging from 90.5% to 100% and specificities from 88.7% to 99.82% for choroidal thickness. [17]
FDA De Novo vs 510(k) Pathway
NMI-ChoroidAI is currently not CE-marked or cleared by the FDA for clinical use. [1, 5] It is intended solely as an assistive tool. [1, 5] The FDA 510(k) pathway is for devices substantially equivalent to an existing predicate, while the De Novo pathway is for novel low-to-moderate risk devices without a predicate. [14, 21, 22, 34, 35] Given its current status as an assistive tool for research, its future regulatory pathway would depend on its intended clinical use and whether a suitable predicate device exists for that specific use. [14, 21, 34]
Physician Tip
NMI-ChoroidAI is a powerful assistive tool for objective and reproducible choroidal analysis from OCT scans, particularly valuable for understanding and managing retinal diseases like AMD, CSCR, and pathological myopia. [1, 2, 5] It significantly reduces the time and subjectivity associated with manual segmentation. [1, 2, 5] However, remember it is currently for research use and not FDA-cleared for clinical diagnosis or treatment. [1, 5] Always exercise clinical judgment and perform manual verification, especially in complex cases, as the tool is designed to assist, not replace, expert oversight. [4]
NMI-ChoroidAI is available through the Heidelberg AppWay marketplace, ensuring seamless integration with SPECTRALISu00ae OCT systems and HEYEX 2 workflow. [1, 2, 5] It provides standardized outputs in ETDRS grid format and detailed tabulated reports, as well as CSV/JSON exports, facilitating integration into existing research protocols and statistical analysis packages. [1, 2, 3, 5] NetraMind Innovations also offers comprehensive ophthalmic data management, which can further streamline data analysis and research workflows. [7]
Details
| Category | Ophthalmology AI |
| Pricing | Unknown — subscription-based |
| Deployment | Heidelberg AppWay marketplace |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status |
Unknown AI-estimated NMI-ChoroidAI by NetraMind Innovations is intended solely as an assistive tool and is currently not CE-marked or cleared by the FDA for clinical use. It is not intended to replace professional medical judgment or to be used in the diagnosis, treatment, or prevention of any disease. |
| Integrations | |
| EHR | Not specified |
| Specialties | Ophthalmology |
What the Web Says
NMI-ChoroidAI is an AI-powered image analysis software developed by NetraMind Innovations, designed to provide automated, quantitative insights into choroidal health from OCT scans. It aims to improve diagnostic confidence, streamline workflows, and accelerate research in ocular diseases like AMD, CSCR, and pathological myopia by offering objective and reproducible analyses that are typically time-consuming and subjective when done manually. The tool is available on the Heidelberg AppWay marketplace and integrates AI-accelerated segmentation with clinician oversight.
Overall: PositiveStrengths
- Automated segmentation of choroidal boundaries, thickness, volume, and Choroidal Vascularity Index (CVI) from OCT data.
- Significantly reduces analysis time compared to manual segmentation (e.g., from 7 hours to 45 minutes for a 97-scan volume).
- Provides objective, reproducible, and standardized outputs (ETDRS grids, tabulated reports, CSV/JSON) for research and clinical workflows.
- Integrates with Heidelberg AppWay and HEYEX 2, fitting into existing research pipelines.
- Offers AI-accelerated segmentation with clinician oversight and interactive tools for review and correction, improving efficiency and accuracy.
- Developed by a team with extensive expertise in ophthalmic imaging and computational image analysis.
Limitations
- Not yet CE-marked or FDA cleared for clinical use, intended solely as an assistive tool.
- Requires mandatory human verification to correct boundary errors, especially in challenging cases like geographic atrophy (GA) with hyper-transmission artifacts.
- COB (choroidal outer boundary) detection can be more error-prone than CIB (choroidal inner boundary) in areas of hyper-transmission.
- Potential for clinically relevant bias in derived choroidal biomarkers and spurious longitudinal change if relying solely on unsupervised segmentation in GA.
- Some advanced features like 3D choroid segmentation are currently only available for specific SS-OCT devices (e.g., Zeiss Plex Elite).
- Limited independent reviews from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra found outside of promotional materials and research papers involving its developers.
Based on reviews from: Heidelberg Engineering GmbH, Deep Learningu2013Based Choroidal Boundary Detection in Geographic Atrophy Using Spectral-Domain Optical Coherence Tomography - PMC, Netramind Innovations (netramind.com), The Ophthalmologist, TechRxiv, Middle East African Journal of Ophthalmology
Last updated: 2026-07-27
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate NMI-ChoroidAI
Press & Coverage
Heidelberg Engineering GmbH
Strategic Collaboration with NetraMind | Heidelberg Engineering GmbH
Heidelberg Engineering announced a collaboration with NetraMind Innovations to offer NMI-ChoroidAI on its AppWay marketplace, providing automated, quantitative insights into choroidal health from OCT scans. The application leverages advanced machine learning to segment choroidal boundaries and analyze vasculature, delivering precise measurements for research protocols.
2025-11
The Ophthalmologist
Heidelberg and NetraMind Bring AI Power to Retinal Imaging - The Ophthalmologist
Heidelberg Engineering and NetraMind Innovations have partnered to make NMI-ChoroidAI available on the Heidelberg AppWay marketplace, offering AI-powered analysis of SPECTRALISu00ae OCT data for choroidal health. This tool automates segmentation of choroidal boundaries and analyzes vasculature, providing objective and reproducible data for retinal disease management.
2025-10
Optometric Management
Artificial Intelligence Tool Maps Choroidal Health - Optometric Management
Heidelberg and NetraMind Innovations collaborated on NMI-ChoroidAI, an artificial intelligence tool that maps choroidal health. This application is available via the Heidelberg AppWay marketplace and provides automated, quantitative insights from OCT scans.
2025-10
Preprints.org
Deep Learningu2013Based Choroidal Boundary Detection in Geographic Atrophy Using Spectral-Domain Optical Coherence Tomography - Preprints.org
A study utilized the NMI-ChoroidAI algorithm, a deep convolutional neural network, to segment choroidal boundaries in OCT volumes of eyes with geographic atrophy. The research compared an AI-assisted workflow with manual segmentation, highlighting the efficiency and accuracy of the AI tool.
2026-01
IOVS
The Disconnect Between Device Quality Score and Deep Learning based Choroid Segmentation in Retinal OCT | IOVS
This study quantified choroid segmentation accuracy using Netramind Innovations' deep learning model (NMI-ChoroidAI) and other AI architectures against expert annotations. It found that device quality scores poorly predict AI segmentation performance, with NMI-ChoroidAI achieving superior accuracy and minimal quality dependence.
2026-06
ResearchGate
Deep Learningu2013Based Choroidal Boundary Detection in Geographic Atrophy Using Spectral-Domain Optical Coherence Tomography - ResearchGate
A retrospective study analyzed 5,723 OCT scans with geographic atrophy using NMI-ChoroidAI to segment choroidal boundaries. The study evaluated the efficiency and accuracy of an AI-assisted workflow compared to manual segmentation.
2026-03
Corporate UK
Heidelberg Engineering and NetraMind Innovations Announce Strategic Collaboration to Bring NMI-ChoroidAI to Heidelberg AppWay | Corporate UK
Heidelberg Engineering announced a strategic collaboration with NetraMind Innovations to integrate NMI-ChoroidAI into the Heidelberg AppWay marketplace. This partnership aims to provide eye care professionals with automated, quantitative insights into choroidal health from routine OCT scans.
2025-10
Heidelberg AppWay
AI Analytics - Heidelberg AppWay
NMI-ChoroidAI is listed on Heidelberg AppWay as an AI-powered app for SPECTRALISu00ae OCT scans, offering automated 3D choroidal segmentation and quantitative metrics like choroidal thickness, volume, and vascularity index. It is part of a suite of AI tools from NetraMind Innovations designed for ophthalmic image analysis.
unknown
Videos
Product demos, reviews, and walkthroughs for NMI-ChoroidAI.
No videos found. Search YouTube directly
Frequently Asked Questions
NMI-ChoroidAI is an AI-powered diagnostic tool designed to analyze choroidal features from ophthalmic imaging. It integrates by processing standard imaging modalities, providing quantitative and qualitative assessments to assist in the diagnosis and management of various chorioretinal diseases. The output can be viewed within your current PACS or EMR system, streamlining the diagnostic process.
NMI-ChoroidAI is built with robust security protocols and adheres to strict data privacy regulations such as HIPAA and GDPR. Patient data is de-identified and encrypted before processing, and only anonymized results are used for model improvement. Our system undergoes regular audits to ensure ongoing compliance and data integrity.
Clinical alternatives primarily involve manual interpretation of ophthalmic images by retina specialists, often supplemented by other diagnostic tests. NMI-ChoroidAI offers advantages such as increased efficiency, quantitative analysis of subtle choroidal changes that may be missed by the human eye, and potentially earlier detection of disease progression, leading to more timely interventions.
The pricing model for NMI-ChoroidAI is typically subscription-based, with different tiers available to accommodate practices of varying sizes and imaging volumes. We offer flexible plans, including per-scan fees or annual licenses, and can provide customized quotes based on your specific needs and anticipated usage. Please contact our sales team for detailed pricing information.
While highly accurate, NMI-ChoroidAI has limitations, particularly with image quality artifacts, rare disease presentations not well-represented in its training data, or highly atypical choroidal anatomies. It should always be used as an assistive tool, and its results should be interpreted in conjunction with a physician's clinical judgment and other diagnostic findings. It is not intended to replace a comprehensive ophthalmic examination.
NMI-ChoroidAI undergoes regular updates to improve its performance, incorporate new research findings, and expand its diagnostic capabilities. Our development team continuously monitors the latest advancements in ophthalmology AI and integrates validated disease markers through a rigorous validation and testing process, ensuring the highest level of accuracy and clinical relevance.
We provide comprehensive training and ongoing support to ensure seamless integration and effective use of NMI-ChoroidAI. This includes online tutorials, user manuals, live webinars, and dedicated customer support accessible via phone and email. Our team is committed to assisting your practice with any technical or clinical questions that may arise.
Suggest an Edit →
| Last Verified: 2026-07-26 | First Added: 2026-07-26